Genetic pathway in molecular pathogenesis of myelodysplastic syndrome
Genetic pathway in molecular pathogenesis of myelodysplastic syndrome
批准号:
17590998
负责人:
HARADA Hironori
金额:
$2.3万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2006
中文摘要
点击翻译按钮获取中文摘要
英文摘要
AML1/RUNX1 mutations have been reported frequently in myelodysplastic syndrome (MDS) patients. Although AML1 mutations are suspected to play a pivotal role in the development of MDS/AML, acquisition of additional genetic alterations is also necessary. We analyzed gene alterations in MDS/AML patients with AML1 mutations, comparing them to alterations in those without an AML1 mutation. AML1 mutations were significantly associated with-7/7q-, whereas MDS/AML patients without AML1 mutations showed a high frequency of-5/5q-and a complex karyotype. Patients with AML1 mutations showed more mutations of their FLT3, N-RAS, PTPN11, and NF1 genes, resulting in a significantly higher mutation frequency for receptor tyrosine kinase (RTK)-RAS signaling pathways in AML1-mutated MDS/AML patients compared to AML1-wildtype MDS/AML patients (38% versus 6.3%, P<.0001). Conversely, p.53 mutations were detected only in patients without AML1 mutations. Furthermore, blast cells of the AML1-mutated patients expressing surface c-KIT, and SHP-2 mutants contributed to prolonged and enhanced ERK activation following SCF stimulation. Our results suggest that MDS/AML arising from AML1/RUNX1 mutations has a significant association with-7/7q-alteration, and frequently involves RTK-RAS signaling pathway activation.We performed mouse bone marrow transplantation using bone marrow cells transduced with AML1 mutants. Most mice developed MDS/AML-like symptoms within several months after the transplant. The expression patterns of some genes have been changed by immigration of retrovirus vectors harboring AML1-mutations, and these genes seemed to collaborate with AML1 mutants to develop MDS/AML. We also tried to transduce AML1 mutation into human hematopoietic stem cells, and found their morphological changes and abnormal proliferation. Now we continue this project. Furthermore, we found that CEBPA gene mutation is one of the master events to develop MDS/AML without AML1 mutation.
期刊论文(29)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Point mutations in the AML1/RUNXI gene associated with myelodysplastic syndrome.
与骨髓增生异常综合征相关的 AML1/RUNXI 基因点突变。
DOI:
--
发表时间:
2005
期刊:
Critical Reviews^<TM> in Eukaryotic Gene Expression 15(3)
影响因子:
--
作者:
[Harada H, et al.]
通讯作者:
et al.
Implications of somatic mutations in the AMLI/RUNXI gene in myelodysplastic syndrome (MDS) : Future molecular therapeutic directions for MDS.
AMLI/RUNXI 基因体细胞突变对骨髓增生异常综合征 (MDS) 的影响:MDS 的未来分子治疗方向。
DOI:
--
发表时间:
2006
期刊:
Current Cancer Drug Targets 6
影响因子:
--
作者:
[Harada H, et al.]
通讯作者:
et al.
AML1点異変を有する骨髄異形成症候群(MDS)の多段階発症メカニズムの解明
阐明具有 AML1 点突变的骨髓增生异常综合征 (MDS) 的多步发病机制
DOI:
--
发表时间:
2006
期刊:
長崎医会誌 81・supp1
影响因子:
--
作者:
[Yano, H., Komatsu H., et al., Kohara J., Li Fu-Jun, 原田浩徳 他]
通讯作者:
原田浩徳 他
Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome (MDS).
与骨髓增生异常综合征 (MDS) 相关的 AML1/RUNX1 基因点突变。
DOI:
--
发表时间:
2005
期刊:
Acta Medica Nagasakiensia 50(suppl. 1)
影响因子:
--
作者:
[Harada H, et al.]
通讯作者:
et al.
別冊・医学のあゆみ血液疾患Ver.3-State of arts
单册:医学血液病史Ver.3-艺术现状
DOI:
--
发表时间:
2005
期刊:
影响因子:
--
作者:
[Takei, Y., Mizukami, H., Saga, Y., Yoshimura, I., Hasumi, Y., Takayama, T., Kohno, T., Matsushita, T., Okada, T., Kume, A., Suzuki, M., Ozawa, K., Kimura R, Kirito K et al., 原田浩徳(分担執筆)]
通讯作者:
原田浩徳(分担執筆)
共 19 条
Molecular mechanisms of myelodysplastic syndromes (MDS) using RUNX1-mutated iPS cells derived from familial MDS patients
-
批准号:24591398
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.41万
-
财政年份:2012
-
负责人:HARADA Hironori
-
依托单位:
Establishment of new classification in myeloid neoplasms for personalized medicine
-
批准号:21591206
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2009
-
负责人:HARADA Hironori
-
依托单位:
AML1 point mutations play a pivotal role in the pathogenesis of MDS/AML
-
批准号:19591114
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2007
-
负责人:HARADA Hironori
-
依托单位:
Proteomic analysis of AML1/RUNX1 mutant complexes
-
批准号:15591008
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:2003
-
负责人:HARADA Hironori
-
依托单位:
国内基金
海外基金
登录
查看更多内容
RUNX1通过BMP2/Smad信号轴调控肿瘤相关巨噬细胞M2极化促进膀胱癌进展的机制研究
-
批准号:2026JJ81626
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:黎勇林
-
依托单位:
三尖刺血经RUNX1下调CMPK2磷酸化减轻Ox-mtDNA介导的小胶质细胞炎症反应治疗急性缺血性卒中的机制研究
-
批准号:2026JJ82023
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:肖靓宜
-
依托单位:
USP11/RUNX1正反馈环路抑制免疫原性细胞死亡促进结直肠癌进展的机制研究
-
批准号:JCZRQN202501352
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
化瘀解毒方调控RUNX1介导自噬依赖性NETosis改善急性脑梗死的机制研究
-
批准号:2025JJ50566
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:李定祥
-
依托单位:
RUNX1 正向调控 CCL1-CCR8 轴诱导 ILC2 活化参与过敏性哮喘机制研究
-
批准号:2025JJ60715
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:蒋媛媛
-
依托单位:
RUNX1调控巨噬细胞M1极化及重编程促进糖尿病肾脏病进展的作用及分子机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:关美萍
-
依托单位:
基于RUNX1/RIP3MLKL内源性程序性坏死途径研究消瘤藤总善豆素抵抗肺癌EGFR-TKI耐药的作用机制
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:黎疆
-
依托单位:
功能性子宫内膜类器官靶向RUNX1调控TGF β1/SMAD3通路促进宫腔粘
连再生修复的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
转录因子RUNX1调控代谢重编程增强脂质合成促进肾透明细胞癌进展的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:30.0万元
-
批准年份:2024
-
负责人:邓煜麟
-
依托单位:
LINC02820介导RUNX1可变剪切增敏TNF/NF-κB信号促进食管鳞癌转移及免疫逃逸
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:黄必军
-
依托单位: